Casa Sollievo Della Sofferenza

At Casa Sollievo Della Sofferenza, a major share of research in Neoplasms and Hemic and Lymphatic Diseases focuses on cancers such as multiple myeloma, diffuse large B-cell lymphoma, acute leukemias, and melanoma. These studies are designed to test new treatment combinations, improve disease control, and refine strategies for patients with relapsed, refractory, or newly diagnosed cancer.

• Blood cancers including multiple myeloma, lymphoma, and acute lymphoblastic leukemia
• Solid tumors such as colorectal cancer, gastric cancer, and pancreatic cancer
• Melanoma and other advanced malignancies

The research portfolio includes trials evaluating innovative immunotherapies, targeted therapies, and combination approaches aimed at improving survival and reducing relapse.

The site has a strong program in Digestive System Diseases and Nutritional and Metabolic Diseases, with trials in Crohn’s disease, ulcerative colitis, inflammatory bowel disease, NASH, and primary biliary cholangitis. Research here is centered on better control of inflammation, improved healing of the bowel, and therapies that may slow or reverse liver damage.

• Crohn’s disease and ulcerative colitis
• NASH, MASH, and other chronic liver disorders
• Studies aiming to improve symptom control, tissue healing, and long-term outcomes

Several trials are testing new biologic and metabolic therapies to help patients achieve deeper and more durable remission.

Clinical trials in Cardiovascular Diseases, Immune System Diseases, and Nutritional and Metabolic Diseaseschronic kidney disease, IgA nephropathy, hypertension, and kidney complications in type 2 diabetes. These studies are evaluating whether new or combined treatments can better protect kidney function and reduce disease progression.

• Chronic kidney disease and IgA nephropathy
• Kidney disease linked to diabetes and hypertension
• Trials focused on slowing decline in renal function and improving proteinuria control

The research also includes efforts to improve treatment choices based on biopsy findings and to evaluate therapies that may lower inflammation and cardiovascular risk.

A substantial part of the program addresses Immune System Diseases and Skin and Connective Tissue Diseases, with studies in myasthenia gravis, graft-versus-host disease, juvenile psoriatic arthritis, and other immune-mediated conditions. The goal is to test treatments that can calm abnormal immune activity while improving quality of life.

• Generalized myasthenia gravis
• Chronic and acute graft-versus-host disease
• Juvenile psoriatic arthritis and related inflammatory conditions

These trials often compare new biologic medicines with existing care to see whether they can provide better symptom relief and longer-lasting disease control.

Research in Nervous System Diseases and Congenital, Hereditary, and Neonatal Diseases and Abnormalities includes studies of epilepsy, Huntington’s disease, amyotrophic lateral sclerosis, and hypophosphatasia. These trials are aimed at understanding disease mechanisms and testing therapies for conditions with limited treatment options.

• Focal epilepsy and refractory partial onset epilepsy
• Huntington’s disease and amyotrophic lateral sclerosis
• Hypophosphatasia and other rare inherited disorders

The research focus is on improving neurological function, reducing symptoms, and exploring new options for rare diseases that need more effective therapies.

Casa Sollievo Della Sofferenza also contributes to pediatric and adolescent oncology research within Neoplasms and Diseases of the Hemic and Lymphatic System. Trials include high-risk neuroblastoma, acute lymphoblastic leukemia, and lymphoblastic lymphoma, with a focus on improving cure rates and reducing relapse in younger patients.

• High-risk neuroblastoma
• Childhood and adolescent acute lymphoblastic leukemia
• Lymphoblastic lymphoma and related rare pediatric cancers

These studies are designed to refine treatment effectiveness while supporting safer and more durable long-term outcomes for children and adolescents.